These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17379101)

  • 1. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel therapeutic targets for multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Anderson KC
    J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving disease biology from the lab to the clinic.
    Anderson KC
    Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel biological therapies for the treatment of multiple myeloma.
    Richardson PG; Mitsiades CS; Hideshima T; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):619-34. PubMed ID: 16026741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
    Yasui H; Hideshima T; Richardson PG; Anderson KC
    Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenomics to target myeloma in the bone marrow microenvironment.
    Anderson KC
    Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting multiple myeloma cells and their bone marrow microenvironment.
    Pagnucco G; Cardinale G; Gervasi F
    Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The malignant clone and the bone-marrow environment.
    Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of multiple myeloma].
    Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
    G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: thalidomide as a treatment for multiple myeloma.
    Kumar S; Anderson KC
    Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
    Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.